Efficacy and safety of therapeutic strategies against amyloid-ß peptides in Alzheimer’s disease: a systematic review and web application-based meta-analysis of large phase III clinical trials
Year: 2024
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Alzheimer disease (AD) is a big problem for the scientific community and our societies. It is the most common neurodegenerative disease in aging and the most common dementia, accounting for an estimated 60-80% of all dementia cases (Alzheimer's_Association, 2021). There is no agreement on the cause of this disease. The prevailing hypothesis posits that misfolding and aggregation of amyloid-beta (Aß) peptides lead to tau deposition and subsequent progressive neurodegeneration and cognitive impairment. Therefore, it was thought that drugs targeting toxic Aß species could reduce their accumulation and lead to clinical improvement (Panza, Lozupone, Logroscino, & Imbimbo, 2019). In recent years, amyloid hypothesis was tested in phase III clinical trials with several potent monoclonal antibodies (mAbs) that target Aß (Plotkin & Cashman, 2020). This resulted in the accelerated approval of aducanumab (Aduhelm®) and lecanemab (Leqembi®) by the Food and Drug Administration (FDA) in the U.S., raising both hopes and controversies (Elisabeth Mahase; E. Mahase, 2023). Up to date, no mAbs are authorized for use in AD patients outside the U.S. The main concerns surrounding these drugs are questionable clinical efficacy and adverse effects, above all cerebral edema, microbleeds and hemosiderosis (Cummings, Aisen, et al., 2021; Cummings et al., 2023). Ongoing phase IV trials are expected to give us more complete picture on these drugs, however, it seems that the results of these studies will not be available soon. For instance, the confirmatory phase IV trial for Aduhelm® is estimated to be completed in three years from now, leaving a large uncertainty for patients and healthcare professionals (J. Murphy et al., 2022). Part I of this work systematically reviews recent (from 2014) clinical trials, follow-up and review studies focused on anti-Aß drugs, in order to summarize and analyze their current clinical potential. Promising therapies are ighlighted together with newly developed biomarkers and therapeutic strategies acting on early AD changes. Part II consists of web-based application, AlzMeta.app, that performs a meta-analysis in R to evaluate the efficacy and safety of anti- Aß mAbs in large, randomized placebo-controlled phase III clinical trials. The meta-analysis included 14,980 sporadic AD patients in 14 studies investigating four mAbs: bapineuzumab, solanezumab, lecanemab, and aducanumab. To this extent, this work provides a reproducible evaluation and an objective comparison of different therapeutic interventions in AD. The application is freely available at: https://alzmetaapp.shinyapps.io/alzmeta/ and can be easily updated and scaled up in the future. Our data shows that experimental drugs targeting Aß pathology have not been able to significantly reduce memory impairment and AD progression. Initially, the clinical trials were focused on small molecules that interfere with Aß metabolism. As these strategies have shown no efficacy, alternative approaches were developed in recent years, including immunotherapy and modulators of Aß removal or aggregation. Anti-Aß mAbs have demonstrated the most promising results so far, and the results of our meta-analysis revealed that these drugs statistically improved cognitive, functional and biomarker outcomes. The cognitive effects were strongly correlated with and, therefore, may be predicted by biomarkers of Aß and tau pathology. However, while cognitive effects were of small effect sizes, these drugs considerably increased risk of side effects such as cerebral microbleeds and edema. Together, our findings indicate that anti-Aß treatment still has many obstacles to overcome, and the risk/benefit ratio of current anti-Aß mAbs remains unfavorable. We suggest that early AD detection and Aß oligomer-specific therapies should be accompanied with novel biomarkers and pharmacological strategies acting on other processes known to occur early in AD, including abnormal cholesterol metabolism and neuronal hyperexcitability that impairs cognition, tau pathology, oxidative stress, and epigenetic changes.
Author: Jeremic, Danko
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7199200990
